<SEC-DOCUMENT>0001209191-20-054376.txt : 20201008
<SEC-HEADER>0001209191-20-054376.hdr.sgml : 20201008
<ACCEPTANCE-DATETIME>20201008210533
ACCESSION NUMBER:		0001209191-20-054376
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20201008
FILED AS OF DATE:		20201008
DATE AS OF CHANGE:		20201008

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			KING RICHARD
		CENTRAL INDEX KEY:			0001013702

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39594
		FILM NUMBER:		201231930

	MAIL ADDRESS:	
		STREET 1:		C/O KOS PHARMACEUTICALS INC
		STREET 2:		1001 BRICKELL AVE 25TH FL
		CITY:			MIAMI
		STATE:			FL
		ZIP:			33131

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SPRUCE BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001683553
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				812154263
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		2001 JUNIPERO SERRA BLVD., SUITE 640
		CITY:			DALY CITY
		STATE:			CA
		ZIP:			94104
		BUSINESS PHONE:		(415) 294-1687

	MAIL ADDRESS:	
		STREET 1:		2001 JUNIPERO SERRA BLVD., SUITE 640
		CITY:			DALY CITY
		STATE:			CA
		ZIP:			94104
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>doc3.xml
<DESCRIPTION>FORM 3 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2020-10-08</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001683553</issuerCik>
        <issuerName>SPRUCE BIOSCIENCES, INC.</issuerName>
        <issuerTradingSymbol>SPRB</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001013702</rptOwnerCik>
            <rptOwnerName>KING RICHARD</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>2001 JUNIPERO SERRA BOULEVARD, SUITE 640</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>DALY CITY</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94014</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Executive Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.44</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2029-07-22</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>58095</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.44</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2029-10-13</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>175570</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.64</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2030-06-07</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>216174</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>3.07</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F4"/>
            </exerciseDate>
            <expirationDate>
                <value>2030-08-06</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>310197</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">29,048 shares subject to the stock option vested on July 23, 2019.  The remaining shares subject to the stock option vest over a six-month period commencing December 6, 2019, with 1/12th of the shares vesting on a monthly basis.  The shares subject to the stock option are also eligible for accelerated vesting in the event of a successful agreement with the FDA regarding the remainder of Phase 2 and a Phase 3 program leading to an acceptable label, as determined by the Company's board of directors.</footnote>
        <footnote id="F2">The shares subject to the stock option are early exercisable, subject to the Issuer's right of repurchase, and vest over a four-year period commencing October 1, 2019, with 1/48th of the shares vesting on a monthly basis.</footnote>
        <footnote id="F3">All of the shares subject to the stock option are early exercisable, subject to the Issuer's right of repurchase.  40,513 of the shares subject to the stock option vest over a four-year period commencing February 19, 2020, with 1/48th of the shares vesting on a monthly basis following the closing of the Issuer's initial public offering, and 175,661 shares of which vest over a four-year period commencing February 19, 2020, with 1/48th of the shares vesting on a monthly basis.</footnote>
        <footnote id="F4">All of the shares subject to the stock option are early exercisable, subject to the Issuer's right of repurchase.  57,942 of the shares subject to the stock option vest over a four-year period commencing August 7, 2020, with 1/48th of the shares vesting on a monthly basis following the closing of the Issuer's initial public offering, and 252,255 shares of which vest over a four-year period commencing August 7, 2020, with 1/48th of the shares vesting on a monthly basis.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Samir Gharib, Attorney-in-Fact</signatureName>
        <signatureDate>2020-10-08</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.1
<SEQUENCE>2
<FILENAME>attachment1.htm
<DESCRIPTION>EX-24.1 DOCUMENT
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY>
<PRE>
POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints
Samir Gharib with
full power of substitution, the undersigneds true and lawful attorney-in-fact
to:

(1) execute for and on behalf of the undersigned, in the undersigneds capacity
as an officer,
director and/or more than 10% stockholder of Spruce Biosciences, Inc. (the
Company),
Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange
Act of 1934
and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned which
may be necessary
or desirable to complete and execute any such Form 3, 4, or 5, complete and
execute any
amendment or amendments thereto, and timely file such form with the SEC and any
stock
exchange or similar authority; and
(3) take any other action of any type whatsoever in connection with the
foregoing which, in the
opinion of such attorney-in-fact, may be of benefit to, in the best interest of,
or legally
required by, the undersigned, it being understood that the documents executed by
such
attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney
shall be in
such form and shall contain such terms and conditions as such attorney-in-fact
may approve
in such attorney-in-facts discretion.
The undersigned hereby grants such attorney-in-fact full power and authority to
do and perform any
and every act and thing whatsoever requisite, necessary, or proper to be done in
the exercise of any of the
rights and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if
personally present, with full power of substitution or revocation, hereby
ratifying and confirming all that such
attorney-in-fact, or such attorney-in-facts substitute or substitutes, shall
lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted. The
undersigned acknowledges that
the foregoing attorneys-in-fact, in serving in such capacity at the request of
the undersigned, are not assuming,
nor is the Company assuming, any of the undersigneds responsibilities to comply
with Section 16 of the
Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required
to file Forms 3, 4, and 5 with respect to the undersigneds holdings of and
transactions in securities issued by
the Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing
attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of
September 23, 2020.

/s/ Richard King



</PRE>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
